RxDoctor Payments Data

Adam Lowe, MD

Gastroenterology · Chandler, AZNPI 1184624025

Payments from drug & device makers

$8,839in general payments, 2019–2025

Across 455 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Bristol Myers Squibb$848
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$794
  • Pfizer$639
  • Johnson & Johnson$552
  • Ferring Pharmaceuticals Inc.$363
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$8,75999%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,839 in reported general payments places this provider in the 65th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$194,242
Medicare patients
661
Services billed
1,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$245,554
LinzessLinaclotide39$49,656
Mesalamine17$12,448
Mesalamine ErMesalamine60$12,345
Pantoprazole Sodium759$9,807
ClenpiqSod Picosulf/Mag Ox/Citric Ac43$7,438
Colestipol Hcl66$5,603
Dexlansoprazole DrDexlansoprazole11$4,372
Sucralfate57$3,757
Dicyclomine Hcl118$2,843
Budesonide DrBudesonide43$2,665
Lubiprostone11$2,413
Ondansetron OdtOndansetron41$2,226
Azathioprine20$1,955
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,009$49,65639 claims
Ferring Pharmaceuticals Inc.Clenpiq$363$7,43843 claims
Braintree Laboratories, Inc.Sutab$14$1,78211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →